Study aim: investigating the effect of empagliflozin on non-alcoholic fatty liver in type 2 diabetic patients referred to Loghman Hakim Hospital in 1400 Design: Sampling method: The non-probability sampling method will be targeted. In this way, random method is not used in selecting patients in each group, but from the available patients, patients in each group will be selected based on the researcher's judgment up to the specified volume (70 people in each group) according to the purpose of the study. Settings and conduct: The present study, after obtaining permission from the ethics committee of Shahid Beheshti University of Medical Sciences and the consent of the head of the internal department of Loghman Hakim Hospital, will be conducted as a clinical trial on 140 type 2 diabetic patients referred to the endocrine / diabetes / gastrointestinal clinic in 1400. Patients are equally divided into control and treatment groups. In the treatment group, in addition to the standard treatment, they will receive 10 mg of Empagliflozin daily for 6 months. In the control group, patients received only standard treatment and did not receive Empagliflozin. Participants/Inclusion and exclusion criteria: Inclusion criteria: Patients with type 2 diabetes in the age group of 20 to 70 years who are candidates for treatment with Empagliflozin. No history of Empagliflozin use -GFR> 35ml / min / 1.73mn2 -HbA1c≤7.5% Intervention groups: Patients with type 2 diabetes and fatty liver treated with empagliflozin and placeo Main outcome variables: Practical goals: 1.determining the level of insilin level,alt,ast,alkp,GGT,billi,FBS,HbA1c before and 3 and 6 months after the start of treatment 2.determining the degree of fatty liver by U.S and MRI before and 3 and 6 months after start if treatment 3.determining weigt and BMI before and 3 and 6 months after start of teratment